VECT
NASDAQVectivBio Holding AG
Latest news
25 items- PRMemo Therapeutics AG appoints Paul Carter as ChairpersonPRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a
- PRenGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsenGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
- PRVicore Expands and Strengthens its Board of DirectorsSTOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
- 13D/GSEC Form SC 13G/A filed by VectivBio Holding AG (Amendment)SC 13G/A - VectivBio Holding AG (0001836379) (Subject)
- SECSEC Form EFFECT filed by VectivBio Holding AGEFFECT - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form EFFECT filed by VectivBio Holding AGEFFECT - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form EFFECT filed by VectivBio Holding AGEFFECT - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form POS AM filed by VectivBio Holding AGPOS AM - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form POS AM filed by VectivBio Holding AGPOS AM - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form POS AM filed by VectivBio Holding AGPOS AM - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form S-8 POS filed by VectivBio Holding AGS-8 POS - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form S-8 POS filed by VectivBio Holding AGS-8 POS - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form 6-K filed by VectivBio Holding AG6-K - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form 25 filed by VectivBio Holding AG25 - VectivBio Holding AG (0001836379) (Filer)
- 13D/GSEC Form SC 13D filed by VectivBio Holding AGSC 13D - VectivBio Holding AG (0001836379) (Subject)
- PRAlentis Therapeutics Appoints Luca Santarelli as ChairpersonSantarelli is a Proven Leader with a Track Record of Building Successful Biotech Companies Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today the appointment of Dr. Luca Santarelli as the Chair of its Board of Directors. Rafaèle Tordjman, former chair of Alentis, will remain on Alentis' board. "I'm pleased to welcome Luca as chair of our board. His experience as a serial biotech entrepreneur and Alentis board member since 2021 are of great value to our board and company," said Dr. Roberto Iacone, Chief Executive Officer of Alentis. "I very much want to thank Rafaèle for her trem
- SECSEC Form SC 14D9/A filed by VectivBio Holding AG (Amendment)SC 14D9/A - VectivBio Holding AG (0001836379) (Subject)
- SECSEC Form 6-K filed by VectivBio Holding AG6-K - VectivBio Holding AG (0001836379) (Filer)
- SECSEC Form SC TO-T/A filed by VectivBio Holding AG (Amendment)SC TO-T/A - VectivBio Holding AG (0001836379) (Subject)
- PRIronwood and VectivBio Announce the Completion of the Tender Offer for VectivBio SharesIronwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, and VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the "Shares") for $17.00 per share in cash (the "Tender Offer"). The Depositary for the Tender Offer has advised Ironwood and VectivBio that at the end of the offering period, 59,287,753 Shares had been tendered and not withdrawn pursuant to the Tender Offer and it has received commitments
- SECSEC Form SC TO-T/A filed by VectivBio Holding AG (Amendment)SC TO-T/A - VectivBio Holding AG (0001836379) (Subject)
- SECSEC Form SC 14D9/A filed by VectivBio Holding AG (Amendment)SC 14D9/A - VectivBio Holding AG (0001836379) (Subject)
- SECSEC Form 6-K filed by VectivBio Holding AG6-K - VectivBio Holding AG (0001836379) (Filer)
- PRVectivBio Extraordinary General Meeting of Shareholders Approved All ProposalsBASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting approved each of the proposals of the Board of Directors, which satisfied one of the pending conditions to consummating the tender offer by Ironwood Pharmaceuticals, Inc. ("Ironwood") to acquire all of VectivBio's outstanding registered ordinary shares for $17.00 per share in cash (subject to deduction for any applicable withholding taxes). Consummation of the tender offer remains subject to the t
- SECSEC Form SC 14D9/A filed by VectivBio Holding AG (Amendment)SC 14D9/A - VectivBio Holding AG (0001836379) (Subject)
VECT FAQ
7 questionsWhat does VectivBio Holding AG do?
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.Where does VECT stock trade?
VectivBio Holding AG (VECT) is listed on NASDAQ.What sector and industry is VECT in?
VectivBio Holding AG operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did VectivBio Holding AG go public?
VectivBio Holding AG (VECT) completed its IPO in 2021.What are analysts saying about VECT?
VectivBio Holding AG has had 2 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1800.00 price target on 2022-12-13. Recent price targets range from $1800.00 to $2300.00.What companies are similar to VECT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VECT side-by-side with any of them on Quantisnow.How can I track VECT on Quantisnow?
Quantisnow aggregates VectivBio Holding AG's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VECT to receive live email and push alerts on every new disclosure.